Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Medicago Submits Final Vaccine Data for Canada’s COVID-19 Rolling Review
Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, said on December 16 that it has filed the final portion of data with Health Canada under the rolling submission of its plant-derived COVID-19 vaccine, which was developed using GlaxoSmithKline’s pandemic adjuvant.…
To read the full story
Related Article
- Mitsubishi to Review Biz Plan around Medicago’s COVID Jab, Reexamine Japan Timeline Too
August 4, 2022
- Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
- Medicago/GSK’s COVID-19 Vaccine 71% Effective: PII/III
December 8, 2021
- Mitsubishi to Mull Domestic Manufacturing of COVID-19 Vaccine: Exec
November 4, 2021
- Medicago’s COVID-19 Vaccine Yields Positive Interim Data: PII
May 20, 2021
- Canada Starts Review of Medicago’s Rolling Submission for COVID-19 Vaccine
April 27, 2021
- Medicago/GSK Begins PIII for COVID-19 Vaccine, Mitsubishi Mum on Japan Plan
March 18, 2021
BUSINESS
- ASKA Set to Seek Shareholder OK for Faster Poison Pill Activation
May 27, 2026
- Eylea Biosimilar Shipment Restrictions to Be Lifted on June 5
May 27, 2026
- Bayer’s Low-Dose MRI Contrast Agent Ambelvist Debuts in Japan
May 27, 2026
- Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
- Nippon Kayaku to Take Over AstraZeneca’s Zoladex in Japan
May 26, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…